The Federal Trade Commission is stepping up its crackdown on so-called "junk ... on," FTC Chair Lina Khan said. The agency sent letters to 10 companies, warning that their patent listings were ...
Gabriel: If drug manufacturers don’t remove their junk patent listings, they’ll open themselves up to antitrust lawsuits, and ...
The Federal Trade Commission says drug makers are gaming the system in order to keep drug prices high by filing what it ...
But other companies argue that the FTC’s accusation that their patents are junk isn’t accurate. Gabriel: If drug manufacturers don’t remove their junk patent listings, they’ll open themselves up to ...
The crackdown, which comes six months after FTC challenged 10 pharma majors in a similar fashion, targets so-called “junk” patents — listings the regulator disputes as improper or inaccurate. The most ...
the FTC highlighted specifically its disputes of so-called “junk patent listings” for “blockbuster” weight loss medications. To date, the FTC’s Orange Book patent disputes have been ...
FTC’s latest action targets more than 300 Orange Book patent listings across 10 different companies, which brings the total to more than 400 patent listings across 14 companies and should send a ...
The FTC oversees consumer protections ... Faust: So with respect to these listings, which some people call "junk patents," it makes total sense when you're looking at something like some part ...
The U.S. Federal Trade Commission (FTC) announced last week that it is, for the second time, disputing hundreds of “junk” patents ... “By filing bogus patent listings, pharma companies ...
FTC targets Novo's Ozempic, others in crackdown on 300-plus 'junk' patent listings in FDA database Novo Holding’s proposed buyout of Catalent has sparked conversation across the industry about ...